Patient demographic and baseline characteristics
| Baseline characteristics . | Group A . | Group B previous therapy: chemotherapy + rituximab*n = 28 . | |
|---|---|---|---|
| Previous therapy: chemotherapy alone . | |||
| Stratum AI, n = 33 . | Stratum AII, n = 43 . | ||
| Male, no. | 20 | 23 | 12 |
| Female, no. | 13 | 20 | 16 |
| Age, years (mean ± st dev) | 72.7 ± 7.3 | 71 ± 5.6 | 72.1 ± 6.0 |
| Weight, kg (mean ± st dev) | 70.6 ± 10.7 | 73.4 ± 15.7 | 65.3 ± 15.2 |
| WHO performance status, %; | |||
| 0 | 50.0 | 58.1 | 36.0 |
| 1 | 40.6 | 37.2 | 41.0 |
| 2 | 9.4 | 4.7 | 9.0 |
| Bone marrow involvement, no. (%) | 0 (0) | 2 (4.7) | 2 (7) |
| Bulky tumor greater than 5 cm, % | 37.5 | 37.2 | 52.0 |
| IPI at initial diagnosis, no. (%) | |||
| 1 (low) | 8 (24.2) | 11 (25.6) | 0 (0.0) |
| 2 (low-intermediate) | 9 (27.3) | 14 (32.6) | 8 (28.6) |
| 3 (high-intermediate) | 8 (24.2) | 8 (18.6) | 9 (32.1) |
| Higher than 4 (high) | 3 (9.1) | 7 (16.3) | 8 (28.6) |
| Unknown | 5 (15.2) | 3 (7.0) | 3 (10.7) |
| Response to first-line therapy, no. (%) | n = 33 | n = 43 | n = 26 |
| ORR | 22 (67) | 43 (100) | 17 (65) |
| CR | — | 40 (93) | 10 (38.5) |
| CRu | — | 3 (7) | 3 (11.5) |
| PR | 22 (67) | — | 4 (15) |
| SD | 3 (9) | — | — |
| PD | 8 (24) | — | 9 (35) |
| Baseline characteristics . | Group A . | Group B previous therapy: chemotherapy + rituximab*n = 28 . | |
|---|---|---|---|
| Previous therapy: chemotherapy alone . | |||
| Stratum AI, n = 33 . | Stratum AII, n = 43 . | ||
| Male, no. | 20 | 23 | 12 |
| Female, no. | 13 | 20 | 16 |
| Age, years (mean ± st dev) | 72.7 ± 7.3 | 71 ± 5.6 | 72.1 ± 6.0 |
| Weight, kg (mean ± st dev) | 70.6 ± 10.7 | 73.4 ± 15.7 | 65.3 ± 15.2 |
| WHO performance status, %; | |||
| 0 | 50.0 | 58.1 | 36.0 |
| 1 | 40.6 | 37.2 | 41.0 |
| 2 | 9.4 | 4.7 | 9.0 |
| Bone marrow involvement, no. (%) | 0 (0) | 2 (4.7) | 2 (7) |
| Bulky tumor greater than 5 cm, % | 37.5 | 37.2 | 52.0 |
| IPI at initial diagnosis, no. (%) | |||
| 1 (low) | 8 (24.2) | 11 (25.6) | 0 (0.0) |
| 2 (low-intermediate) | 9 (27.3) | 14 (32.6) | 8 (28.6) |
| 3 (high-intermediate) | 8 (24.2) | 8 (18.6) | 9 (32.1) |
| Higher than 4 (high) | 3 (9.1) | 7 (16.3) | 8 (28.6) |
| Unknown | 5 (15.2) | 3 (7.0) | 3 (10.7) |
| Response to first-line therapy, no. (%) | n = 33 | n = 43 | n = 26 |
| ORR | 22 (67) | 43 (100) | 17 (65) |
| CR | — | 40 (93) | 10 (38.5) |
| CRu | — | 3 (7) | 3 (11.5) |
| PR | 22 (67) | — | 4 (15) |
| SD | 3 (9) | — | — |
| PD | 8 (24) | — | 9 (35) |
st dev indicates standard deviation; SD, stable disease; and PD, progressive disease.